IRCCS Ospedale San Raffaele
Milan, 20132, Italy
NCT Number: NCT05774808
Patients with severe aortic regurgitation (AR) may be affected, in many cases, by a concomitant moderate or severe mitral regurgitation (MR). Tethering of the mitral valve leaflets and/or annular dilatation, both consequences of left ventricular dilatation, represent the most common mechanisms underlying the development of MR which can therefore be defined as "secondary" in this case.
When both mitral and aortic regurgitation are severe, patients show a decreased survival due to the pathophysiological consequences of the combination of these pathological conditions. In this case, surgery on both diseased valves is required to interrupt the natural history of the disease and is widely supported by current guidelines. On the other hand, little is known about the fate and prognostic implications of moderate MR secondary to severe AR and whether or not it should be treated at the time of aortic valve surgery. For this condition, the current guidelines do not provide specific recommendations, referring generically to the decision of the Heart Team.
To date, there are few data describing the evolution of moderate MR in patients undergoing surgery for severe AR and insufficient data to support recommendations regarding the treatment of moderate MR concurrently with treatment of AR, so that this decision is now entrusted to the evaluation of the Heart Team. It is therefore desirable to evaluate the outcomes of these patients.
The aim of this study is to evaluate the short- and long-term fate of secondary moderate MR in patients undergoing aortic valve replacement for severe AR.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Milan, 20132, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An aortic valve prosthesis is surgically implanted to treat AR
Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
Time frame: Through study completion, an average of 7 years
Time frame: Through study completion, an average of 7 years
Time frame: Through study completion, an average of 7 years
Time frame: Through study completion, an average of 7 years
Time frame: Through study completion, an average of 7 years
Michele De Bonis
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03466918
Aortic Regurgitation, Aortic Stenosis
Beijing, China
View Trial DetailsNCT06751368
Aortic Regurgitation, Aortic Stenosis, Subvalvular
Beijing, Beijing Municipality, China
View Trial DetailsNCT03314857
Aortic Regurgitation, Aortic Stenosis
Sichuan, Chengdu, China
View Trial DetailsNCT05515848
Aneurysm, Aortic Aneurysm
Nantes, France
View Trial Details